Two of healthcare’s biggest stories this year could end up being the planned launch of two new gene-sequencing machines from Illumina, Inc. (NASDAQ: ILMN), and the potential approval of Kite Pharma‘s (NASDAQ: KITE) chimeric antigen receptor T-cell therapy. Are you prepared for the potential opportunity associated with these two stories?